Benzyl 2-oxohexanoate | 130317-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl 2-oxohexanoate
• CAS: 130317-29-2
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: SRBRNFQJNBXSJW-UHFFFAOYSA-N

物化性质

• 沸点：
  328.9±21.0 °C(Predicted)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Benzyl 2-oxohexanoate 在 palladium on activated charcoal 氢气 、 sodium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 20.0h， 生成 (2S)-2-[[(2S)-1-[(2-methylpropan-2-yl)oxy]-1-oxo-3-phenylpropan-2-yl]amino]hexanoic acid
  参考文献：
  名称：

  Nonpeptide renin inhibitors employing a novel 3-aza (or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement

  摘要：

  A new series of renin inhibitors has been developed. The inhibitors feature a novel replacement for the P2/P3 dipeptide moiety normally associated with renin inhibitors. The dipeptide replacement was a (2S,4S)-3-aza(or oxa)-2,4-di-alkylglutaric acid amide. Extensive structure-activity relationship studies determined that optimum potency was achieved when inhibitors employed a benzyl and butyl group at the C(4) and C(2) carbon position, respectively. In addition, maximum in vitro potency was obtained when the N-terminus was functionalized by incorporating a 4-(1,3-dioxabutyl)piperidine amide. SAR data suggested that the 1,3-dioxabutyl group (methoxymethyl ether) interacted by hydrogen bonding to groups in the S4 domain of renin. This hypothesis was strengthened when a 4-butylpiperidine amide was substituted and inhibitor potency decreased dramatically. Inhibitors employing this novel dipeptide mimic were prepared by coupling the glutaric acid amides with either the transition-state mimic (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (18) or the hydroxyethylene dipeptide isostere. The glutaric acid amides were prepared by two general procedures. The first procedure involved the reductive amination of alpha-amino acid esters with alpha-keto esters. The second procedure involved the displacement reaction of alpha-bromo esters or acids with alpha-amino acid amides.

  DOI：

  10.1021/jm00088a006
• 作为产物：
  描述：

  2-氧代己酸 、 苯甲醇 以 水 、 甲苯 为溶剂， 反应 6.0h， 生成 Benzyl 2-oxohexanoate
  参考文献：
  名称：

  铜催化共轭加成反应对α，α-二取代呋喃酮的高度化学，对映和区域选择性合成

  摘要：

  据报道，带有α，α-二取代的季位立体中心的呋喃酮具有高度的化学，对映和区域选择性合成能力。在室温下，铜催化的有机铝试剂对不饱和酮酯的对映选择性共轭加成反应，随后发生内酯化反应。呋喃酮的合成转化代表了各种容易实现的方法，这些方法可携带带有季位立体中心的各种环状或无环化合物。

  DOI：

  10.1002/chem.201403446

文献信息

• A Compact Chemical Miniature of a Holoenzyme, Coenzyme NADH Linked Dehydrogenase. Design and Synthesis of Bridged NADH Models and Their Highly Enantioselective Reduction¹
  作者：Nobuhiro Kanomata、Tadashi Nakata

  DOI：10.1021/ja992990y

  日期：2000.5.1

  pyridine-formation reaction of formyl-substituted (vinylimino)phosphorane 4 with methyl propiolate. The bridged NADH models 10a−c effected excellent biomimetic reduction at various temperatures in the presence of magnesium ion to achieve both the enantioselective and stereospecific reduction of the pyruvate analogues 12u−z into chiral lactate analogues 13u−z with 88−99% ee. The high enantioselectivity was almost

  需要辅酶 NADH 的 L-乳酸脱氢酶在无氧糖酵解中催化丙酮酸对映选择性还原为 L-乳酸。作为第一个同手性 ansa 型 NADH 模型，我们设计了桥接 NADH 模型 10a-c，其具有对吡啶并烷结构，用于严格模拟 NADH 生物不对称还原中氢转移的立体特异性。这些模型是从相应的桥接烟酸酯 5 中分几个步骤合成的，该桥接烟酸酯 5 通过我们新的甲酰基取代（乙烯基亚氨基）正膦 4 与丙炔酸甲酯的吡啶形成反应制备。桥接的 NADH 模型 10a-c 在镁离子存在的情况下在不同温度下实现了出色的仿生还原，以实现丙酮酸类似物 12u-z 的对映选择性和立体定向还原成手性乳酸类似物 13u-z，具有 88-99% ee。高对映选择性几乎完全取决于 10a-c 的平面手性，而不取决于它们的取代基的性质。
• Non-peptide renin inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0364804A1

  公开（公告）日：1990-04-25

  A renin inhibiting compound of the formula: wherein A is a substituent; R1 is hydrogen, loweralkyl, substituted loweralkyl or loweralkenyl; X is CH2, CHOH, C(O), O, S, S(O), S02, NH, N(O) or -P(O)O-; R3 is loweralkyl, loweralkenyl or substituted loweralkyl; and T is mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  式中的肾素抑制化合物： 其中 A 是取代基；R1 是氢、低级烷基、取代的低级烷基或低级烯基；X 是 CH2、CHOH、C(O)、O、S、S(O)、S02、NH、N(O)或-P(O)O-；R3 是低级烷基、低级烯基或取代的低级烷基；T 是血管紧张素原的 Leu-Val 裂解位点的模拟物；或其药学上可接受的盐、酯或原药。
• METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0937703A1

  公开（公告）日：1999-08-25

  The present invention is directed to a method for purifying pyruvic acid compounds, which method comprises reacting a pyruvic acid compound of general formula (I): wherein R1 is an optionally substituted lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and R2 is a lower alkyl group, with a bisulfite of general formula (II):         MHSO3     (II) wherein M is NH4 or an alkali metal, to give a bisulfite adduct of the pyruvic acid compound and then decomposing the adduct with an acid. According to the present invention, pyruvic acid compounds can be purified by simple and easy procedures without using purification techniques such as distillation or column chromatography, and the above method is advantageous as a process for the production on an industrial scale.

  本发明涉及一种纯化丙酮酸化合物的方法，该方法包括使通式(I)的丙酮酸化合物反应： 其中 R1 是任选取代的低级烷基、低级烯基、低级炔基、环烷基、芳基或杂环基，R2 是低级烷基，与通式（II）的亚硫酸氢盐反应： MHSO3 (II) 其中 M 为 NH4 或碱金属，以得到丙酮酸化合物的亚硫酸氢盐加合物，然后用酸分解该加合物。根据本发明，丙酮酸化合物可以通过简单易行的程序进行纯化，而无需使用蒸馏或柱层析等纯化技术，上述方法作为一种工业规模的生产工艺是非常有利的。
• NON-PEPTIDE RENIN INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP0437508A1

  公开（公告）日：1991-07-24
• EP0437508A4
  申请人：——

  公开号：EP0437508A4

  公开（公告）日：1991-11-06